Biotech Values

[DewDiligence]

ASNS IPOs 4.6M* shares @$10.00:

https://globenewswire.com/news-release/2017/11/16/1193834/0/en/Arsanis-Announces-Pricing-of-Initial-Public-Offering.html

Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases.

…The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in a Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.

*Assuming exercise of underwriter’s option.